The value of immunoglobulin (Ig) for replacement therapy in patients with primary antibody deficiency was realised in the early 1950's and its immunosuppressive effects a decade later.' Initially maternal source Ig preparations were used to enhance cadaveric renal graft survival2 and plasma, as a source of Ig, was used to treat idiopathic thrombocytopenic purpura. 34 As an immunosuppressive agent, Ig did not, however, gain wide application until 1981; this followed a chance observation by Imbach et al,5 who in the course of intravenous immunoglobulin treatment of children with hypogammaglobulinaemia noted that the platelet count of two such children with coincidental idiopathic thrombocytopenic purpura suddenly improved after the infusion of intravenous Ig. This observation was soon confirmed both in children67 and adults"'0 with acute and chronic forms of idiopathic thrombocytopenic purpura. It has been subsequently and amply shown that the platelet response is more favourable in the acute form of the disease" 12 where it may, however, be difficult to distinguish sustained increases in platelet count from spontaneous remissions. Prolonged and unmaintained remission after intravenous Ig treatment is rare in chronic idiopathic thrombocytopenic purpura, but most such patients obtain a transient rise in the platelet count (for a few weeks), often ensuring adequate time and haemostasis for splenectomy or other essential surgery.
Apart from preoperative preparation, intravenous Ig may also be successful in deferring or avoiding splenectomy while booster infusions may sustain remission in patients in whom steroids are contraindicated. In recent years the potential therapeutic value of intravenous Ig has been extended to a broad spectrum ofdisorders, particularly those with a confirAccepted for publication 21 July 1988 med or suspected autoimmune aetiology including other blood cytopenias and diseases affecting the nervous, cardiovascular, endocrine, alimentary and other systems. The treatment protocols and clinical results are detailed in recent reviews. '3 14 Despite this relatively long background of intensive research and clinical application the mechanism underlying the immunomodulatory effect of intravenous Ig has tantalisingly eluded a unified and universally acceptable explanation. This deficiency may result from several factors: (i) intravenous Ig may have more than one mode of action; (ii) subtle variations in the constituents of different intravenous Ig preparations or batches may lead to differences in therapeutic activity, potency, and efficacy; and (iii) the disease being treated, immune based thrombocytopenia although superficially, a single clinical entity is more likely to be a syndrome of covert and variable pathenogenesis. Our prime objective in this article is to review critically and evaluate the bewildering number of explanatory mechanisms which have been proposed to date. '" or alternatively enhancement of their functional activity.'2 Indeed, it has been documented that IgG inhibits pokeweed mitogeninduced B cell differentiation and causes non-specific suppression ofpolyclonal IgG biosynthesis in vitro. '3 While the decrease in platelet-associated IgG following intravenous Ig treatment has been interpreted as signifying suppression of platelet antibody production,'336 some have regarded the fall as indicating a blocking effect by intravenous Ig against the attachment of platelet antibody to platelet'5" or even simply as representing dilution of the platelet antibody by the rising platelet count."' Even more perplexing are reports of actual increases in platelet-associated IgG following intravenous Ig treatment4"l' and of platelet antibody titres in the serum having increased'5 or decreased'0 with treatment. Such contradictory and baffling discrepancies may, however, merely reflect methodological differences or unreliability in the assay techniques currently used for measuring platelet antibodies.
ANTIBODY AUTOREGUILATION
In 1974 Jerne proposed that antibody-producing cells may autoregulate by a network of idiotype/antiidiotype interactions.5' There is no current evidence, however, to indicate that intravenous Ig influences this autoregulatory process. IGG2 DEFICIENCY It has been suggested that IgG2 deficiency may have a role in the pathogenesis of idiopathic thrombocytopenic purpura and that intravenous Ig corrects this defect and by an unknown mechanism suppresses autoantibody production.28 SPECIFIC 
ANTI-FCyR ANTIBODY
The presence of specific anti-FcyR antibody in intravenous Ig reduces autoantibody production (as detailed below).
Increased platelet production and release Uchida et al found no evidence to support this hypothesis but confirmed that platelet survival is prolonged by intravenous Ig treatment.52 It is pertinent that in several studies where plasma, as a source of IgG, has been used in idiopathic thrombocytopenic purpura, the platelet response has been similar to that of intravenous 1g.53 The thrombocytopenia might not, however, have had an immune basis-at least in some such patients. Thus plasma infusions were found to maintain an adequate platelet count for several years in a patient with congenital thrombopoietin deficiency5' and similarly in an adult patient with thrombo-1251 1252 cytopenia. Atrah et al, although failing to elicit a clinically important increase in the platelet count with two courses of high dose intravenous Ig, repeatedly induced a sustained platelet remission with plasma infusions (unpublished observations).
Suppression of natural killer cell activity This may be partly responsible for the immediate as well as the delayed responses to intravenous Ig.
Specific anti-FcyR in intravenous Ig This hypothesis recently postulated by Sandilands et al
has not yet gained wide or adequate recognition. 55 Because we consider it to be ofparamount importance in unravelling the immunomodulatory action of intravenous Ig, a more detailed account of the mechanism and its implications follows.
The main proposition is that intravenous Ig contains an antibody which is directed against and reacts specifically with FcyR (anti-FcyR) and that its action may vary with clinical circumstance and the target cell. Thus in idiopathic thrombocytopenic purpura the FcyR of mononuclear phagocytes blocked or modulated by the Fab portion ofanti-FcyR have no or a reduced binding capacity for the Fc portion of the platelet antibody. Consequently, platelets and their bound antibody complex cannot be phagocytosed by the effector cells ofthe reticuloendothelial system. This mechanism provides insight into several different aspects of intravenous Ig treatment in idiopathic thrombocytopenic purpura and other immune disorders. Firstly, it could explain as indicated above the immediate and transient effect of intravenous Ig. Secondly, the "blocked" FcyR may be internalised as happens when it reacts with immune complexes, resulting in loss or modulation of target cell reactivity be it phagocytic, suppressor, helper or natural killer. It may therefore be the basis of the less common but sustained effect of intravenous Ig in idiopathic thrombocytopenic purpura through either reduced antibody production or decreased phagocytic activity of the reticuloendothelial system, or both. Thirdly, as the Fab (and not the Fc) portion of anti-FcyR is the key reactant with FcyR, unmodified as well as modified intravenous Ig can exert a therapeutic effect with the former being more effective because of the larger molecule exerting greater steric resistance for the Fc portion of other IgG molecules, including platelet antibody from displacing the Fab portion of the anti-FcyR. Fourthly, it may account for the decrease in lymphocytes24 and reduced natural killer cell activity39 accompanying intravenous Ig treatment because these cells bear FcyR.56 The proposed mechanism gains additional support from the clinical demonstration that infusion of a murine-derived monoclonal anti-FcyR is capable of reproducing all Atrah, Davidson the in vivo and in vitro effects of intravenous Ig. 57 Because anti-D has been shown to be effective in idiopathic thrombocytopenic purpura,58 9 it has been suggested that the success of intravenous Ig may be related to its anti-D content.i' On the other hand, another study using a different anti-D preparation and at higher doses, failed to elicit a clinically important platelet response in idiopathic thrombocytopenic purpura.6' From these disparate findings, we conclude that the active therapeutic agent may not be anti-D itself but some other constituent and venture to suggest that this is most likely to be anti-FcyR which is present in both anti-D62 and intravenous Ig63 preparations.
The plausibility of this FcyR blockade is further promoted by some recent findings in aplastic anaemia where remission has been achieved by the use of intravenous Ig.' There, the therapeutic effect has been attributed to a substantial reduction in the number of lymphocytes belonging to an FcyR bearing subset known to suppress haemopoiesis in patients with aplastic anaemia.65 Short of bone marrow transplantation, the most effective agents in the treatment of aplastic anaemia are anti-lymphocyte globulin (ALG) or anti-thymocyte globulin (ATG), although their mode of action remains undefined.6"7 Recently, however, anti-FcyR antibody has been detected in ALG and ATG available from three different manufacturers.68 Based on this and other evidence it has been proposed that in idiopathic thrombocytopenic purpura and aplastic anaemia the beneficial responses induced by ALG, ATG, and intravenous Ig are related to the presence of a common therapeutic principle. If anti-FcyR is the active ingredient in intravenous Ig, it would be wasteful to continue using a crude and expensive preparation such as intravenous Ig in large doses for routine treatment; a new product (perhaps prepared from the plasma of pregnant women or deliberately immunised volunteers or modified monoclonal antibody) containing a "blend" of anti-FcyR concentrates which could be used at smaller doses and lower cost would be preferred to conventional high dose intravenous Ig. The substitution of intravenous Ig by anti-D in the treatment ofautoimmune disorders is to be discouraged because anti-D is a scarce human resource primarily intended for the prevention of Rhesus alloimmunisation.76 Furthermore, the mechanism of action of anti-D itself is uncertain.77 Although supportive evidence is awaited, anti-D may prevent rhesus alloimmunisation because of its antiFcyR content. This hypothesis could be verified by comparing the ability of a standard anti-D preparation from which anti-FcyR has been removed for monoclonal anti-D and anti-FcyR which contains no anti-D to prevent alloimmunisation in rhesus D negative male volunteers injected with D-positive cells. Anti-D remains in short supply because only donations with a high anti-D content are avccepted for its preparation. If the anti-D content is shown to be therapeutically irrelevant, future interest will centre on anti-FcyR activity, and plasmas with high concentrations may be more readily available.
As intravenous Ig treatment is immunosuppressive it is therefore prudent to exercise caution in its administration to immunocompromised or neutropenic patients78 where the resultant reduction of FcyR function may predispose to fulminant infection. While intravenous Ig does not induce generalised phagocytic blockade and is well tolerated by non-immune compromised patients,79 the effect ofits long term administration in high doses to healthy subjects is not known, particularly with regard to natural killer cell activity and immunosurveillance. Furthermore, it is theoretically possible that it may either induce immune complex disease if FcyR-anti-FcyR complexes are deposited in tissues and organs, or amyloidosis from accumulation of the degradation products of massive quantities administered over several years. Further research is required to provide definitive solutions to those novel challenges and problems.
Finally, despite the considerable volume ofevidence supporting our hypothesis embodying FcyR blockade, we accept that conclusive proof awaits further elucidation ofseveral ofits essential aspects. These include the mode of action of anti-FcyR on modifying cellular activity and the mechanism of the lymphopenia; the association between clinical response and the changes in FcyR-bearing lymphocytes; which of the three known types of FcyR`t forms the target for the antiFcyR and the relation of FcyR, a functional marker, to the currently applied cluster differentiation system of lymphocyte subset typing.
